Company: RGBP
Filing Date: 2025-09-08
Form Type: 253G1
Source: 0001641172-25-026822
Chunk: 79

Company: Regen BioPharma Inc
Filing Date: 2025-09-08
Form: 253G1
Chunk 79
---
 |  (5,217,372 | ) |
| TOTAL LIABILITIES & STOCKHOLDERS’ EQUITY (DEFICIT)                                                                                |     | $         |     169,482 |   |     | $             |     161,084 |   |

The Accompanying Notes are an Integral Part of These Financial Statements

All stock amounts have been retroactively adjusted to reflect a 1 for 1500 reverse stock split of all issued series of stock effective as of March 6, 2023

| 66 |

<div align='center'>REGEN BIOPHARMA, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(unaudited)</div>

| Net revenue:                                                                              |     | Period Ended March 31 
 3 Months              
 2025                  |       2025 |   |     | 2024 |      2024 |   |     | 6 Months 
 2025     |     2025 |   |     | 2024 
 2024 |           |   |
|:------------------------------------------------------------------------------------------|:----|:----------------------|-----------:|:--|:----|:-----|----------:|:--|:----|:---------|---------:|:--|:----|:-----|----------:|:--|
| Revenues                                                                                  |     | $                     |     31,640 |   |     |      |    31,640 |   |     |          |   63,280 |   |     |      |    63,280 |   |
| Revenues, Related Party                                                                   |     |                       |     27,425 |   |     |      |    27,424 |   |     |          |   54,850 |   |     |      |    54,849 |   |
| Net revenue                                                                               |     |                       |     59,065 |   |     |      |    59,064 |   |     |          |  118,130 |   |     |      |   118,129 |   |
| Operating expenses:                                                                       |     |                       |            |   |     |      |           |   |     |          |          |   |     |      |           |   |
| Research and Development                                                                  |     |                       |          - |   |     |      |    40,133 |   |     |          |        - |   |